Free 24-hour delivery over £75 · Same-day dispatchOrder before 2pm - same-day dispatch · Free 24-hour delivery over £75
Research use only
Kovalabs supplies research-grade peptides to qualified researchers for laboratory use only. They are not medicines, are not for human or animal consumption, and are supplied with no dosing or medical guidance.
You must be 18 or over and a qualified person purchasing solely for scientific research.
Selecting ‘I agree’ confirms the above and your acceptance of our Research Disclaimer and Terms of Sale.
Research use only
· 4 min read
Two peptides get lumped together so often in soft-tissue research literature that researchers occasionally assume they work the same way. They do not. BPC-157 and TB-500 sit on opposite sides of the mechanism map - one a synthetic pentadecapeptide with angiogenic and cell-signalling activity, the other a thymosin beta-4 fragment that operates primarily through actin dynamics and cytoskeletal regulation. The complementarity of those two pathways is precisely what makes them a recurring pairing in tissue-repair research designs. Everything below describes what published studies have investigated, not any human use; both compounds are supplied strictly as research reagents.
BPC-157 is a synthetic 15-amino-acid sequence - a pentadecapeptide - with no endogenous counterpart in the full-length form used in research. The published literature places its primary mechanistic interest in angiogenic signalling, cytoprotection and extracellular-matrix interactions in experimental in-vitro and in-vivo models. Cell-migration assays and studies of vascular signalling pathways form the bulk of the mechanistic literature; the compound does not have a single established receptor target in the way that, say, a GPCR agonist does. That open-ended pharmacology has attracted a disproportionate volume of research relative to its time in the catalogue, and also a disproportionate volume of marketing noise - the two being unrelated quantities.
TB-500 is a synthetic fragment of thymosin beta-4, the endogenous actin-sequestering protein. Its mechanism sits downstream of actin polymerisation: the fragment is studied for its role in regulating actin monomer availability, cell-migration pathways and cytoskeletal reorganisation. Where BPC-157 research tends to focus on vascular and matrix signalling, TB-500 research centres on the machinery cells use to move and reorganise their internal architecture - a meaningfully different entry point into tissue-repair biology, and one that does not overlap mechanistically with the angiogenic pathways BPC-157 targets.
Complementary pathways invite co-investigation, and the pairing of angiogenic signalling (BPC-157) with cytoskeletal regulation (TB-500) follows the same logic that drives any multi-component experimental design: if the hypothesised processes sit upstream and downstream of one another, or operate in parallel on the same tissue substrate, then studying them in isolation answers a narrower question than studying them in combination. That research rationale is why the Tissue Repair Stack combines them. A third compound, GHK-Cu - the copper-binding glycyl-L-histidyl-L-lysine tripeptide - is a common addition where matrix-remodelling and collagen-related pathways are also under investigation, again on mechanistic grounds rather than any shared chemical ancestry.
BPC-157 and TB-500 are supplied by Kovalabs for laboratory and in-vitro research only. Neither is a medicine, a supplement, nor approved for human or veterinary use. Nothing on this page describes a dose, a route, a schedule or an outcome. Both compounds are investigational and have not been evaluated by the MHRA or any comparable regulator for safety or efficacy in humans or animals. Every batch ships with a certificate of analysis. See the full research disclaimer for terms.